The review concluded that in patients with high-risk cutaneous melanoma, interferon-alpha adjuvant treatment showed statistically significant improvements in both disease free survival and overall survival. This conclusion reflected the results of the review, but the unknown quality of the included trials and the potential for bias within the review suggest that the authors' conclusions should be interpreted with caution.
resolved by consensus. When time-to-event data were not directly reported in the trials, log rank hazard ratios and variance were estimated for each trial; where this was not possible, Kaplan-Meier survival curves were used to generate statistics for meta-analysis (method of Parmar et al). Authors of the included trials were contacted for missing or unclear data.
Methods of synthesis
The pooled hazard ratios, together with 95% confidence intervals, were calculated using a fixed-effect and randomeffects meta-analysis. Meta-analysis was weighted by the inverse of variance. Statistical heterogeneity was assessed using the X 2 and I 2 statistic. Publication bias was assessed using funnel plot analysis, Egger's linear regression, Begg's test, and the trim and fill method.
Subgroup analysis was undertaken according to dose/type of interferon-alpha, stage of disease, comparator, adequate number of patients, and calculating or estimating hazard ratios.
